4//SEC Filing
Aryeh Jason 4
Accession 0002001011-24-000055
CIK 0000886163other
Filed
Jun 17, 8:00 PM ET
Accepted
Jun 18, 9:25 PM ET
Size
9.3 KB
Accession
0002001011-24-000055
Insider Transaction Report
Form 4
Aryeh Jason
Director
Transactions
- Award
Non-Qualified Stock Option (right to buy)
2024-06-14+5,444→ 5,444 totalExercise: $80.06Exp: 2034-06-14→ Common Stock (5,444 underlying) - Award
Common Stock
2024-06-14+1,252→ 78,080 total
Holdings
- 5,025(indirect: By Trust)
Common Stock
- 51,594(indirect: Indirect)
Common Stock
Footnotes (3)
- [F1]Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
- [F2]All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds.
- [F3]Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
Documents
Issuer
LIGAND PHARMACEUTICALS INC
CIK 0000886163
Entity typeother
Related Parties
1- filerCIK 0001376960
Filing Metadata
- Form type
- 4
- Filed
- Jun 17, 8:00 PM ET
- Accepted
- Jun 18, 9:25 PM ET
- Size
- 9.3 KB